Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Development and clinical evaluation of a cost-effective method with capillary electrophoresis sequencer-based fragment analysis assay panel for genetic classification and risk stratification in de novo AML

View Full Paper
Ask AI
Bookmark
Share

Authors

KMKohei MorimotoKYKimikazu Yakushijin

Discussion

Loading...

Member takes

Overview

Clinical evaluation confirms a capillary electrophoresis assay for genetic classification and risk stratification in AML, highlighting cost-effectiveness and accuracy compared to Sanger sequencing.

Key Points

  • The aim was to develop a cost-effective screening system for genetic testing in de novo AML.
  • Developed a multiplex fragment analysis system using capillary electrophoresis
  • Assessed performance on 53 patient samples
  • Compared with Sanger sequencing as the control method
  • Achieved 100% accuracy compared to Sanger sequencing
  • Detected specific mutations in NPM1 and FLT3-ITD
  • Confirmed detection even in low-frequency variants

Cite This Study

Morimoto et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc24https://doi.org/10.1182/blood-2025-7854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Verifying Cost Effective Conventional PCR as an Alternative to NGS in Detecting FLT3-ITD in AML at Diagnostic Time Point – A Cross Sectional Study From a Tertiary Care Centre in North India2026
  2. 2Abstract 4628: Validation of an automated, scalable comprehensive genomic profiling assay for hematologic malignancies2024 · 1 citations
  3. 3Abstract 3834: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system2026
  4. 4Abstract 5300: Clinical utility of whole genome sequencing for upfront risk stratification in AML and MDS patients2026
  5. 5How to Read a Next-Generation Sequencing Report for AML and MDS? What Hematologists Need to Know2025